Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cassava Sciences Inc

2.79
+0.18006.90%
Post-market: 2.75-0.0400-1.43%19:55 EDT
Volume:1.05M
Turnover:2.90M
Market Cap:134.78M
PE:-1.91
High:2.80
Open:2.61
Low:2.61
Close:2.61
Loading ...

Chinese Drug Administration Accepts Application of Centergate Technologies' Unit for Oxycodone Hydrochloride Tablets

MT Newswires Live
·
14 Mar

Cassava Sciences Amends Bonus Plan After Court Settlement

TIPRANKS
·
12 Mar

Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?

Zacks
·
08 Mar

H.C. Wainwright Sticks to Their Hold Rating for Cassava Sciences (SAVA)

TIPRANKS
·
05 Mar

H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal

TIPRANKS
·
05 Mar

Protega Pharmaceuticals collaborates with Wellgistics to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™

GlobeNewswire
·
04 Mar

Cassava Sciences Reports 2024 Financial Results and Strategic Updates

TIPRANKS
·
04 Mar

Cassava Sciences Q4 2024 GAAP EPS $(0.57) Beats $(0.66) Estimate, $128.6M In Cash And Cash Equivalents

Benzinga
·
03 Mar

BRIEF-Cassava Sciences Q4 Basic EPS USD -0.57

Reuters
·
03 Mar

Cassava Sciences Q4 Operating Expenses USD 29.487 Million

THOMSON REUTERS
·
03 Mar

Cassava Sciences Q4 Basic EPS USD -0.57

THOMSON REUTERS
·
03 Mar

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

GlobeNewswire
·
03 Mar

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires Live
·
28 Feb

Sector Update: Health Care Stocks Higher Thursday Afternoon

MT Newswires Live
·
28 Feb

Cassava Sciences Licenses Simufilam Patent From Yale University for Potential Treatment of Seizures; Shares Rise

MT Newswires Live
·
28 Feb

Cassava Sciences licenses simufilam method of treatment patent

TIPRANKS
·
27 Feb